If you have EDS and you're considering a GLP-1, read this part first

This comes up constantly and it rarely gets said plainly, so here it is.

GLP-1 receptor agonists — semaglutide, tirzepatide and the newer triple agonists — work partly by slowing how fast the stomach empties. That is not a side effect, it is part of the mechanism. Food stays in the stomach longer, you feel full sooner, you eat less.

Now the other half. Gastrointestinal dysmotility is common in hypermobile EDS. Delayed gastric emptying, reflux, early satiety and nausea show up often enough that gastroenterologists who know EDS look for them routinely.

Why that combination deserves care

If your stomach already empties slowly, a drug whose job is to slow it further is not a neutral addition. The people who struggle most on these drugs tend to be the ones who had GI problems before starting, and that describes a large share of the EDS population.

This is not an argument that nobody with EDS should take them. Plenty of people with EDS also have type 2 diabetes or obesity, and these are genuinely effective drugs with strong trial evidence behind them. It is an argument that the decision needs a gastroenterologist who knows your history, not a forum thread.

What to actually ask

• Have I been assessed for delayed gastric emptying, and should I be before starting?
• If I already have dysmotility, does that change the titration schedule or rule it out?
• What symptoms mean stop and call you, rather than push through?
• How do we protect muscle mass while losing weight, given my joints depend on it?

That last one matters more in EDS than in the general population. Muscle is what compensates for ligaments that do not hold. Losing it alongside fat is a worse trade for you than for most people.

The compound pages for PLP-1 S, PLP-2 T and PLP-3 R go through the mechanisms, the approval status and the label warnings in more detail.